Vinblastine(Vincaleukoblastine)

Molecular Weight (MW)	810.97
Formula	C46H58N4O9
CAS No.	865-21-4
Storage	-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)	DMSO: 100 mg/mL (110.0 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Chemical Name	(3aR,3a1R,4R,5S,5aR,10bR)-methyl 4-acetoxy-3a-ethyl-9-((5S,7R,9S)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)-2,4,5,6,7,8,9,10-octahydro-1H-3,7-methano[1]azacycloundecino[5,4-b]indol-9-yl)-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate
Synonyms	NSC49842; Vincaleucoblastine, Velban, NSC-49842; NSC 49842; Velsar, VLB

Molecular Weight (MW)

810.97

Formula

C46H58N4O9

CAS No.

865-21-4

Storage

-20℃ for 3 years in powder form

-80℃ for 2 years in solvent

Solubility (In vitro)

DMSO: 100 mg/mL (110.0 mM)

Water: <1 mg/mL

Ethanol: <1 mg/mL

Chemical Name

(3aR,3a1R,4R,5S,5aR,10bR)-methyl 4-acetoxy-3a-ethyl-9-((5S,7R,9S)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)-2,4,5,6,7,8,9,10-octahydro-1H-3,7-methano[1]azacycloundecino[5,4-b]indol-9-yl)-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate

Synonyms

NSC49842; Vincaleucoblastine, Velban, NSC-49842; NSC 49842; Velsar, VLB

In Vitro	In vitro activity: The average terminal half-lives of Vinblastine is 14.3 h. When incubated in freshly isolated rat hepatocytes, VLB penetrates rapidly and intensely into the cells, probably through a passive diffusion mechanism followed by tight cellular binding. Vinblastine inhibits the angiogenic response induced by adrenomedullin and is also positive for mitotic slippage, causing micronuclei in mononucleate cells with cytokinesis block. vinblastine gives significant increase in micronucleated mononucleated cells at concentrations that produced approximately 50% cell death and cytostasis or less as calculated using RPD, RICC and RCC. Cell Assay: Six-well treatment plates are set up that contained 5 × 104 cells/mL (Chinese hamster ovary (CHO) cells) in each well, suspended in 3 mL culture medium, and these are treated with vinblastine for 3 h followed by 21 h growth.
In Vivo	Vinblastine is a widely used anticancer drug with undesired side effects. A combination of VBL and RAP at very low doses against human HCC gets a satisfactory antiangiogenic effect in vivo. The clinically relevant dose of vinblastine inhibits palmitoylation of tubulin in vivo in CEM cells (effect on depalmitoylation of tubulin).
Animal model
Formulation & Dosage
References	Proc Soc Exp Biol Med. 1993 Jul;203(3):372-6; Oncogene. 2003 Sep 25;22(41):6458-61.

In Vitro

In vitro activity: The average terminal half-lives of Vinblastine is 14.3 h. When incubated in freshly isolated rat hepatocytes, VLB penetrates rapidly and intensely into the cells, probably through a passive diffusion mechanism followed by tight cellular binding. Vinblastine inhibits the angiogenic response induced by adrenomedullin and is also positive for mitotic slippage, causing micronuclei in mononucleate cells with cytokinesis block. vinblastine gives significant increase in micronucleated mononucleated cells at concentrations that produced approximately 50% cell death and cytostasis or less as calculated using RPD, RICC and RCC.

Cell Assay: Six-well treatment plates are set up that contained 5 × 104 cells/mL (Chinese hamster ovary (CHO) cells) in each well, suspended in 3 mL culture medium, and these are treated with vinblastine for 3 h followed by 21 h growth.

In Vivo

Vinblastine is a widely used anticancer drug with undesired side effects. A combination of VBL and RAP at very low doses against human HCC gets a satisfactory antiangiogenic effect in vivo. The clinically relevant dose of vinblastine inhibits palmitoylation of tubulin in vivo in CEM cells (effect on depalmitoylation of tubulin).

Animal model

Formulation & Dosage

References

Proc Soc Exp Biol Med. 1993 Jul;203(3):372-6; Oncogene. 2003 Sep 25;22(41):6458-61.

CAS NO:	865-21-4
规格:	≥98%

包装	价格(元)
10mg	询价
25mg	询价
50mg	询价
100mg	询价
250mg	询价
500mg	询价
1g	询价